Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome.

@article{Zinzani2010GemcitabineAS,
  title={Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome.},
  author={Pier Luigi Zinzani and Filippo Venturini and Vittorio Stefoni and Maria Paola Fina and Cinzia Pellegrini and Enrico Derenzini and Letizia Gandolfi and Alessandro Broccoli and Lisa Argnani and Federica Quirini and Stefano A Pileri and Michele Baccarani},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2010},
  volume={21 4},
  pages={
          860-3
        }
}
BACKGROUND Peripheral T-cell lymphoma unspecified (PTCLU) and mycosis fungoides (MF) often show resistance to conventional chemotherapy. Gemcitabine should be considered a suitable option. We report the long-term update of 39 pretreated T-cell lymphoma patients treated with gemcitabine. PATIENTS AND METHODS From May 1997 to September 2007, 39 pretreated MF and PTCLU patients received gemcitabine. Inclusion criteria were as follows: histologic diagnosis of MF or PTCLU; relapsed/refractory… CONTINUE READING
Highly Cited
This paper has 111 citations. REVIEW CITATIONS

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 60 CITATIONS, ESTIMATED 54% COVERAGE

111 Citations

02040'11'13'15'17'19
Citations per Year
Semantic Scholar estimates that this publication has 111 citations based on the available data.

See our FAQ for additional information.

References

Publications referenced by this paper.
SHOWING 1-10 OF 33 REFERENCES

Final clinical results of a phase 2 NCI multicenter study or romidepsin in recurrent cutaneous T-cell lymphoma (molecular analyses included)

  • S Bates, R Piekarz, J Wright
  • Blood
  • 2008
1 Excerpt

Low-dose pralatrexate (PDX) is active in cutaneous T-cell lymphoma: preliminary results of a multicenter dose finding trial

  • S Horwitz, M Duvic, Y Kim
  • Ann Oncol ;
  • 2008
1 Excerpt

PROPEL: a multi-center phase 2 openlabel study of pralatrexate (PDX) with vitamin B12 and folic acid supplementation in patients with relapsed or refractory peripheral T-cell lymphoma

  • OA O’Connor, B Pro, L Pinter-Brown
  • Blood
  • 2008
1 Excerpt

Zanolimumab ( HuMaxCD 4  ) , a fully human monoclonal antibody : efficacy and safety in patients with relapsed or treatmentrefractory noncutaneous CD 4 + T - cell lymphoma

  • F d’Amore, J Radford, M Jerkeman
  • Blood
  • 2007

A phase I open label dose escalation study to evaluate MEDI-507 in patients with CD2-positive T-cell lymphoma/leukemia

  • DA Casale, NL Bartlett, DD Hurd
  • (Abstr
  • 2006

Similar Papers

Loading similar papers…